Anti-D administration

Rhesus D (Rh D) negative women are at risk of alloimmunisation resulting in the development of Anti-D antibodies. These are able to cross the placenta causing haemolysis to such an extent that the fetus/ newborn is at risk of serious morbidity and mortality.

The administration of passive Anti-D at times of actual and potential feto-maternal haemorrhage (FMH) and routine prophylaxis has been shown to reduce the rate of alloimmunisation.

Guidelines have been established for the recommended use of Anti-D in pregnancy and postpartum, these recommendations are endorsed by RANZCOG, Australian Red Cross Blood Services, National Health and Medical Research Council, and Australasian/New Zealand Blood Transfusions Guidelines.

Anti-D guidelines